Medical/Pharmaceuticals News & Press Release Distribution

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

YOKOHAMA, Japan, Sept. 2, 2021 /PRNewswire/ -- REPROCELL have signed a Strategic Collaboration Agreement with TEXCELLJAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter "TEXCELL") is a contract manufacturing organization (CMO) head...

2021-09-02 03:43 1386

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging. This strategic partnership is intended ...

2021-09-01 22:08 2534

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

New data proves technology neutralizes the Delta variant Third Human Trial Underway DURHAM, N.C., Sept. 1, 2021 /PRNewswire/ -- EmitBio, Inc., a life science company, today announced successful results from a new In Vitro Neutralization study of the Delta variant in human airway tissue. The stud...

2021-09-01 21:00 1377

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

New data proves technology neutralizes the Delta variant Third Human Trial Underway DURHAM, N.C., Sept. 1, 2021 /PRNewswire/ -- EmitBio, Inc., a life science company, today announced successful results from a new In Vitro Neutralization study of the Delta variant in human airway tissue. The stud...

2021-09-01 21:00 1546

Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests

SEOUL, South Korea, Sept. 1, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays. Combo Swab is a user-friendly...

2021-09-01 17:40 1395

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer

HOUSTON and SINGAPORE, Sept. 1, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately. Dr....

2021-09-01 17:00 1202

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 1, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) appl...

2021-09-01 13:05 2340

SK magic provides clean air and water to Malaysians at COVID-19 vaccine centers and hospitals

KUALA LUMPUR, Malaysia, Sept. 1, 2021 /PRNewswire/ -- In support of the National COVID-19 Immunisation Programme, SK magic, the leading home appliance company fromSouth Korea, equipped Covid-19 Vaccination Centres (CVCs) and treatment hospitals with its air and water purifiers to provide fresh and...

2021-09-01 11:49 2216

SK magic provides clean air and water to Malaysians at COVID-19 vaccine centers and hospitals

Zymo Research Receives CE Mark for New SafeCollect™ At-Home Sample Collection Kits

Self-collection devices designed for ease of use and safety IRVINE, Calif., Sept. 1, 2021 /PRNewswire/ -- Zymo Research announced today its new line of at-home sample collection kits has received CE marking for sale in the European Union (EU). TheSafeCollect™ Sample Collection Kits were designed...

2021-09-01 11:05 2060

Zymo Research Receives CE Mark for New SafeCollect™ At-Home Sample Collection Kits

SynForU(TM)-HerCare probiotics shows benefits to reduce vaginal yeast infection in pregnant women

KAOHSIUNG, Taiwan, Sept. 1, 2021 /PRNewswire/ -- The first clinical study which has been published in the Journal of Applied Microbiology documents that SynForU™-HerCare is effective in reducing vulvovaginal symptoms and recurrences of vaginal candidiasis (VC) in pregnant women.

2021-09-01 09:00 2752

SynForU(TM)-HerCare probiotics shows benefits to reduce vaginal yeast infection in pregnant women

MedAlliance Announces First Patient Enrolled in the 3,300 Patient Landmark Sirolimus DEB vs DES Study

GENEVA, Sept. 1, 2021 /PRNewswire/ -- MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study "SELUTION DeNovo". This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], versus a limus drug-eluting ...

2021-09-01 08:00 1833

MedAlliance Announces First Patient Enrolled in the 3,300 Patient Landmark Sirolimus DEB vs DES Study

European Stroke Organisation Conference (ESOC) 2021: Non-traditional risk factors for heart attack and stroke rising more steeply in women, major study reveals

BASEL, Switzerland, Sept. 1, 2021 /PRNewswire/ -- Work stress, sleep disorders, and fatigue, regarded as non-traditional risk factors for heart attack and stroke, are rising more steeply amongst women than men, according to a new study presented today at the European Stroke Organisation (ESO) Con...

2021-09-01 06:00 1936

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...

2021-08-31 22:05 3043

Jacobio Pharmaceuticals Announces 2021 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech firm reached175 million yuan (approx. US$27 million) for the half year, up 146 percent ye...

2021-08-31 22:01 4045

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...

2021-08-31 19:00 1352

Alithea Genomics Launches BRB-Seq Kits for High-Throughput RNA-Seq of Tissue, Cells and Blood Samples

LAUSANNE, Switzerland, Aug. 31, 2021 /PRNewswire/ -- Alithea Genomics, a rapidly growing player in the transcriptomics field, has announced today the launch of its first MERCURIUS BRB-seq kits, which enable high-throughput and cost-efficient RNA-seq library preparation from a wide range of RNA sa...

2021-08-31 19:00 1761

CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services

MONTRÉAL, Aug. 31, 2021 /PRNewswire/ -- CellCarta and Olink Proteomics AB announced today a strategic collaboration to offerOlink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.

2021-08-31 19:00 1604

CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...

2021-08-31 18:00 1103

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...

2021-08-31 18:00 3226

Elekta Unity MR-Linac featured in 72 abstracts at European radiation oncology congress

MADRID, August 31, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers worldwide, ref...

2021-08-31 14:21 1437